QUICK ANSWER · AEO / GEO
Glutathione is an endogenous antioxidant tripeptide. Reduced GSH, oxidised GSSG, oral and topical formulations, injectable products and GlyNAC precursors must be distinguished. Small human studies show mixed skin and biomarker results: the 2017 oral trial did not show significant overall melanin-index or UV-spot differences versus placebo. Biomarker changes do not establish disease prevention or longer life, and oral/topical evidence does not establish injection safety. Class A refers only to verified Tathion oral medicine in Japan, not skin-whitening approval; Grade C describes the limited human evidence reviewed here. FDA's 27 August 2026 alert reported at least 30 patients with adverse events following IV glutathione involving dietary-supplement-grade material and endotoxin concerns. Exact supplier-product status remains unverified.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Glutathione?
Glutathione is described pharmacologically as Endogenous antioxidant tripeptide / glutathione redox system; route-specific evidence. Glutathione is an endogenous antioxidant tripeptide. Reduced GSH, oxidised GSSG, oral and topical formulations, injectable products and GlyNAC precursors must be distinguished. Small human studies show mixed skin and biomarker results: the 2017 oral trial did not show significant overall melanin-index or UV-spot differences versus placebo. Biomarker changes do not establish disease prevention or longer life, and oral/topical evidence does not establish injection safety. Class A refers only to verified Tathion oral medicine in Japan, not skin-whitening approval; Grade C describes the limited human evidence reviewed here. FDA's 27 August 2026 alert reported at least 30 patients with adverse events following IV glutathione involving dietary-supplement-grade material and endotoxin concerns. Exact supplier-product status remains unverified.
Does Glutathione have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Glutathione approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.